AI News Sentiment & Analysis
Relmada Therapeutics, Inc. (RLMD) — AI News Sentiment & Analysis
4 recent AI analyses of Relmada Therapeutics, Inc. (RLMD) stock news and press releases, with sentiment and confidence scoring updated continuously.
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
BullishEarnings ReleaseIND filings and initiation of Phase 3 RESCUE for NDV-01, and Phase 2 for Sepranolone, all backed by a multi-year cash runway. (Timing: IND filings by year-end 2026; Phase 3/2 initiations upon IND clearance (early 2027 likely).)Aug 7, 2026Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
BullishCorporate EventInclusion in the Russell 2000 and 3000 indexes will lead to automatic purchases by index-tracking funds, creating a demand shock for the stock. (Timing: Immediate to short-term, as index funds adjust portfolios post-reconstitution (effective after June 26, 2026).)Jun 29, 2026Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
BullishEarnings ReleaseInitiation of Phase 3 RESCUE registrational program for NDV-01, leveraging positive Phase 2 data and secured funding. (Timing: Mid-2026)May 12, 2026Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
BullishThe primary catalysts are the initiation of the Phase 3 RESCUE program for NDV-01 and initial 3-month data from this study. (Timing: Phase 3 initiation in mid-2026, with initial 3-month data expected by year-end 2026.)Mar 19, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Relmada Therapeutics, Inc. (RLMD) bullish or bearish right now?
AI Sentiment on RLMD: 4 Bullish.
What was the latest AI analysis for Relmada Therapeutics, Inc. (RLMD)?
The latest analysis was published on 8/7/2026 with the headline: "Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update".
How does Bekodia analyze Relmada Therapeutics, Inc. (RLMD) stock?
Bekodia uses advanced AI models to process Relmada Therapeutics, Inc. (RLMD) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.